Interleukin 18 gene promoter polymorphism: A link between hypertension and pre-hospital sudden cardiac death: The Helsinki Sudden Death Study

European Heart Journal

Volumn 30, Issue 23, 2009, Pages 2939-2946

  Hernesniemi, Jussi A ^a   Karhunen, Pekka J ^a   Oksala, Niku ^a   Kähönen, Mika ^a   Levula, Mari ^a   Rontu, Riikka ^a   Ilveskoski, Erkki ^b   Kajander, Olli ^a   Goebeler, Sirkka ^a   Viiri, Leena E ^a   Hurme, Mikko ^a   Lehtimäki, Terho ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Coronary heart disease; Genetics; Hypertension; Inflammation; Polymorphism; Sudden cardiac death

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 18; MESSENGER RNA;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTOPSY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRANSCRIPTION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN DEATH;

ADULT; AGED; ALLELES; AUTOPSY; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; FINLAND; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOSPITALIZATION; HUMANS; HYPERTENSION; INTERLEUKIN-18; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 71549119220     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp316     Document Type: Article

References (46)

1. Zheng ZJCJ, Giles WH, Ayala CI, Greenlund KJ, Keenan NL, Neff L, Wattigney WA, Mensah GA. State-specific mortality from sudden cardiac death-United States, 1999. MMWR Morb Mortal Wkly Rep 2002;51:123-126.
2. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-1197.
3. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest 2005;115: 2305-2315.
4. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
5. Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995;91:1749-1756.
6. Escobedo LG, Zack MM. Comparison of sudden and nonsudden coronary deaths in the United States. Circulation 1996;93:2033-2036.
7. Friedlander Y, Siscovick DS, Weinmann S, Austin MA, Psaty BM, Lemaitre RN, Arbogast P, Raghunathan TE, Cobb LA. Family history as a risk factor for primary cardiac arrest. Circulation 1998;97:155-160.
8. Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999;99:1978-1983.
9. Kaikkonen KS, Kortelainen ML, Linna E, Huikuri HV. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006;114:1462-1467. Epub 25 September 2006.
10. Arking DE, Chugh SS, Chakravarti A, Spooner PM. Genomics in sudden cardiac death. Circ Res 2004;94:712-723.
11. Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Pessi T, Hurme M, Lehtimäki T. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: the Helsinki Sudden Death Study. Atherosclerosis 2008;196:643-649. Epub 31 August 2007.
12. Liang XH, Cheung W, Heng CK, Wang DY. Reduced transcriptional activity in individuals with IL-18 gene variants detected from functional but not association study. Biochem Biophys Res Commun 2005;338:736-741. Epub 13 October 2005.
13. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146-152.
14. Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Hagiwara K, Ohgawara T, Kuwabara Y, Kawase I, Tanaka T. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun 2006;342:1413-1416. Epub 28 February 2006.
15. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281-312.
16. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, Perret C, Munzel T, Rupprecht HJ, Lackner K, Cambien F, Blankenberg S. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005;112:643-650. Epub 25 July 2005.
17. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598-1603.
18. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001;89: E41-E45.
19. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
20. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-257.
21. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
22. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995;76:24C-33C.
23. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326: 242-250.
24. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002;88:467-469.
25. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
26. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006;4:4.
27. Bis JC, Heckbert SR, Smith NL, Reiner AP, Rice K, Lumley T, Hindorff LA, Marciante KD, Enquobahrie DA, Monks SA, Psaty BM. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis 2008;198:166-173. Epub 5 November 2007.
28. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Schnabel R, Munzel T, Blankenberg S. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 2007;1:1.
29. Mikkelsson J, Perola M, Laippala P, Savolainen V, Pajarinen J, Lalu K, Penttilä A, Karhunen PJ. Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999;19: 2573-2578.
30. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355-1374.
31. Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, Järvinen O, Salenius JP, Ozsait B, Komurcu-Bayrak E, Erginel-Unaltuna N, Huovila AP, Kytömäki L, Soini JT, Kähönen M, Karhunen PJ, Laaksonen R, Lehtimäki T. ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries-Tampere vascular study. Ann Med 2009;41:279-290.
32. Mikkelsson J, Perola M, Penttilä A, Goldschmidt-Clermont PJ, Karhunen PJ. The GPIIIa (beta3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis 2001;154:721-727.
33. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, Lutjohann D, Smet J, Van Coster R, Seppänen-Laakso T, Lehtimäki T, Soini J, Oresic M. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006;1:e97.
34. Sansom DM. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 2000;101:169-177.
35. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-474.
36. Rosso R, Roth A, Herz I, Miller H, Keren G, George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol 2005;98:45-48.
37. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108:2453-2459. Epub 27 October 2003. (Pubitemid 37444405)
38. Barbaux S, Poirier O, Godefroy T, Kleinert H, Blankenberg S, Cambien F, Tiret L. Differential haplotypic expression of the interleukin-18 gene. Eur J Hum Genet 2007;15:856-863. Epub 9 May 2007.
39. Chapman CM, McQuillan BM, Beilby JP, Thompson PL, Hung J. Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Atherosclerosis 2006;189:414-419. Epub 24 January 2006.
40. Marfella R, Siniscalchi M, Nappo F, Gualdiero P, Esposito K, Sasso FC, Cacciapuoti F, Di Filippo C, Rossi F, D'Amico M, Giugliano D. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005;18:308-318.
41. Chandrasekar B, Marelli-Berg FM, Tone M, Bysani S, Prabhu SD, Murray DR. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun 2004;319:304-311.
42. Doi T, Sakoda T, Akagami T, Naka T, Mori Y, Tsujino T, Masuyama T, Ohyanagi M. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/ Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol 2008; 295:H1279-H1287.
43. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340: 115-126.
44. Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angio-tensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005;96:1064-1071.
45. Giles WH, Croft JB, Keenan NL, Lane MJ, Wheeler FC. The validity of self-reported hypertension and correlates of hypertension awareness among blacks and whites within the stroke belt. Am J Prev Med 1995;11:163-169.
46. Wu SC, Li CY, Ke DS. The agreement between self-reporting and clinical diagnosis for selected medical conditions among the elderly in Taiwan. Public Health 2000;114:137-142.